| Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up |
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025. |
zacks.com |
2025-05-09 18:30:20 |
Czytaj oryginał (ang.) |
| What Makes Veracyte (VCYT) a New Buy Stock |
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-08 17:05:35 |
Czytaj oryginał (ang.) |
| Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript |
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer John Leite - Chief Commercial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Puneet Souda - Leerink Partners Colleen Babington - Wolfe Research Tejas Savant - Morgan Stanley Thomas DeBourcy - Nephron Research Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2025 Financial Results Webcast. |
seekingalpha.com |
2025-05-08 04:49:40 |
Czytaj oryginał (ang.) |
| Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates |
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago. |
zacks.com |
2025-05-08 00:00:32 |
Czytaj oryginał (ang.) |
| Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer. |
businesswire.com |
2025-04-25 11:00:00 |
Czytaj oryginał (ang.) |
| Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting. |
businesswire.com |
2025-04-22 13:00:00 |
Czytaj oryginał (ang.) |
| Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release. |
businesswire.com |
2025-04-21 20:05:00 |
Czytaj oryginał (ang.) |
| Should You Continue to Hold Veracyte Stock in Your Portfolio? |
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock. |
zacks.com |
2025-04-17 14:15:46 |
Czytaj oryginał (ang.) |
| Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-15 14:50:36 |
Czytaj oryginał (ang.) |
| Here's Why Veracyte (VCYT) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-14 14:45:36 |
Czytaj oryginał (ang.) |
| Veracyte (VCYT) Just Overtook the 20-Day Moving Average |
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. |
zacks.com |
2025-04-10 14:35:39 |
Czytaj oryginał (ang.) |
| Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? |
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2025-04-10 14:05:46 |
Czytaj oryginał (ang.) |
| Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? |
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-26 14:30:31 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade |
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-03-26 12:55:23 |
Czytaj oryginał (ang.) |
| New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer. |
businesswire.com |
2025-03-25 18:05:00 |
Czytaj oryginał (ang.) |
| Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces 8 Abstracts Highlighting Performance and Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25. |
businesswire.com |
2025-03-19 19:00:00 |
Czytaj oryginał (ang.) |
| Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally? |
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention. |
zacks.com |
2025-03-13 11:45:39 |
Czytaj oryginał (ang.) |
| Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom |
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects. |
zacks.com |
2025-02-27 14:50:18 |
Czytaj oryginał (ang.) |
| Solid Growth, Soft Outlook: Why I'm Holding On Veracyte |
Veracyte, Inc. shows strong revenue growth and market share in genomic diagnostics, particularly with its Decipher and Afirma tests, but faces significant near-term challenges. 2024 ended positively with 23% revenue growth and strong cash flow, yet 2025 will be critical for transitioning to a stable, profit-generating leader. Regulatory uncertainties, Afirma's growth deceleration, and potential financial issues from selling the French subsidiary pose risks to Veracyte's near-term performance. |
seekingalpha.com |
2025-02-25 12:32:13 |
Czytaj oryginał (ang.) |
| Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat |
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests. |
zacks.com |
2025-02-25 11:00:39 |
Czytaj oryginał (ang.) |
| Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript |
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research, LLC Mason Carrico - Stephens Inc. Puneet Souda - Leerink Partners Maggie Boeye - William Blair & Company Lu Li - UBS Group AG Corey Rosenbaum - Scotiabank Subbu Nambi - Guggenheim Securities, LLC Yuko Oku - Morgan Stanley Joseph Conway - Needham & Company, LLC Prashant Kota - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2024 Financial Results webcast. |
seekingalpha.com |
2025-02-25 00:53:03 |
Czytaj oryginał (ang.) |
| Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates |
Veracyte (VCYT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to loss of $0.04 per share a year ago. |
zacks.com |
2025-02-24 20:30:17 |
Czytaj oryginał (ang.) |
| Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I'm incredibly proud of what our team accomplished in 2024,” said Marc Stapley, Veracyte's chief executive officer. “We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant op. |
businesswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Is Veracyte Stock a Good Addition to Your Portfolio Right Now? |
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises. |
zacks.com |
2025-02-21 11:25:30 |
Czytaj oryginał (ang.) |
| Veracyte to Participate in Upcoming Investor Conferences |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 46th Annual Institutional Investors Conference – Orlando, FL Presentation on March 5th at 9:50 a.m. Eastern Time Leerink Partners Global Healthcare Conference – Miami, FL Fireside Chat on March 11th at 8:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by. |
businesswire.com |
2025-02-19 19:05:00 |
Czytaj oryginał (ang.) |
| New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research. |
businesswire.com |
2025-02-14 10:30:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for February 13th |
VCYT and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 13, 2025. |
zacks.com |
2025-02-13 13:01:14 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for February 13th |
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025. |
zacks.com |
2025-02-13 07:56:08 |
Czytaj oryginał (ang.) |
| New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer. |
businesswire.com |
2025-02-05 10:30:00 |
Czytaj oryginał (ang.) |
| Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's we. |
businesswire.com |
2025-02-04 18:30:00 |
Czytaj oryginał (ang.) |
| Veracyte Gains 44% in a Year: What's Driving the Stock? |
VCYT is gaining shares due to the strength of its Afirma and Decipher tests. |
zacks.com |
2025-01-06 10:26:26 |
Czytaj oryginał (ang.) |
| Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now |
Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors. |
zacks.com |
2024-12-27 10:21:12 |
Czytaj oryginał (ang.) |
| Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks? |
The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty. |
zacks.com |
2024-12-19 15:57:29 |
Czytaj oryginał (ang.) |
| 4 Healthcare Technology Innovators to Invest in Before the New Year |
Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT. |
zacks.com |
2024-12-19 14:00:40 |
Czytaj oryginał (ang.) |
| Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025 |
The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth. |
zacks.com |
2024-12-16 18:01:09 |
Czytaj oryginał (ang.) |
| 3 Medical Instruments Industry Stocks to Buy on the GenAI Wave |
MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar their prospects. |
zacks.com |
2024-12-16 14:16:19 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen |
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog. |
zacks.com |
2024-12-12 05:16:11 |
Czytaj oryginał (ang.) |
| This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar |
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage. |
zacks.com |
2024-12-11 12:00:39 |
Czytaj oryginał (ang.) |
| 5 Medical Device Stocks That Survived the 2024 Market Volatility |
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025. |
zacks.com |
2024-12-11 10:55:37 |
Czytaj oryginał (ang.) |
| Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines. |
businesswire.com |
2024-12-05 18:05:00 |
Czytaj oryginał (ang.) |
| Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised |
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests. |
zacks.com |
2024-11-07 13:55:24 |
Czytaj oryginał (ang.) |
| Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript |
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-07 00:49:53 |
Czytaj oryginał (ang.) |
| Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates |
Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago. |
zacks.com |
2024-11-06 21:10:20 |
Czytaj oryginał (ang.) |
| Veracyte to Participate in Upcoming Investor Conferences |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthcare Conference – Rancho Palos Verdes, CA Fireside Chat on November 12th at 2:45 p.m. Eastern Time Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA Fireside Chat on November 13th at 3:00 p.m. Eastern Time Wolfe Research Healthcare Conference – New York, NY Fireside Chat on November. |
businesswire.com |
2024-10-30 19:00:00 |
Czytaj oryginał (ang.) |
| Veracyte: Revolutionizing Noninvasive Cancer Diagnostics |
In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ). |
etftrends.com |
2024-10-21 15:38:02 |
Czytaj oryginał (ang.) |
| Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and. |
businesswire.com |
2024-10-16 22:43:00 |
Czytaj oryginał (ang.) |
| 3 MedTech Stocks to Buy as Monetary Policy Eases |
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy. |
zacks.com |
2024-09-30 16:55:19 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte |
Chicago, IL – September 16, 2024 – Today, Zacks Equity Research discusses Intuitive Surgical ISRG, Masimo Corp. MASI and Veracyte, Inc. VCYT. |
zacks.com |
2024-09-16 10:25:21 |
Czytaj oryginał (ang.) |
| 3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost |
ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects. |
zacks.com |
2024-09-13 16:06:12 |
Czytaj oryginał (ang.) |
| Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now |
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests. |
zacks.com |
2024-09-09 12:30:58 |
Czytaj oryginał (ang.) |
| Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue? |
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-05 16:35:45 |
Czytaj oryginał (ang.) |